uBriGene Biosciences

Shanghai, CN · Boston, MA
AAV Lentiviral Plasmid
Program data pending ClinicalTrials.gov matching · Last scored 2026-03-15
56.5
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (6)

Quick Facts: uBriGene Biosciences

Signal Score
56.5/100 (as of 2026-03-15)
Quality Compliance
Assessment pending
Headquarters
Shanghai, CN · Boston, MA
Modalities
AAV, Lentiviral, Plasmid
Active CGT Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CGT manufacturing intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesAAV, Lentiviral, Plasmid
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 50.0
BIOSECURE Act exposure risk
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
BIOSECURE Act exposure risk
Capacity 63.0
2 CGT manufacturing sites
Regulatory milestones (6 articles)
Sites: Shanghai, China, Boston, MA
Source: SEC EDGAR, press monitoring, company profiles
2 CGT manufacturing sites
Recent Press6 articles
2 CGT manufacturing sites
Regulatory milestones (6 articles)

Recent News 6 articles

regulatory 2026-03-16
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Gene - pharmiweb.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Gene  pharmiweb.com
Source →
regulatory 2026-03-16
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - Rutland Herald
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy  Rutland Herald
Source →
regulatory 2026-03-16
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - BioSpace
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy  BioSpace
Source →
regulatory 2026-03-16
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - Weatherford Democrat
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy  Weatherford Democrat
Source →
regulatory 2026-03-16
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - ACCESS Newswire
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy  ACCESS Newswire
Source →
regulatory 2026-03-16
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy - guardonline.com
uBriGene Congratulates Strategic Partner Grit Biotechnologies on FDA IND Clearance for Its Next-Generation GT307 TIL Therapy  guardonline.com
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs → Lentiviral CDMOs → Plasmid CDMOs →